Pictilisib
Information
- Drug Name
- Pictilisib
- Description
- Entry(CIViC)
- 11
CIViC
| Disease | Mutation | EL | ET | ED | CS | VO | TR | Pubmed | Links |
|---|---|---|---|---|---|---|---|---|---|
| cancer | PIK3CA MUTATION PIK3CA MUTATION | D |
Predictive
|
Does Not Support
|
Sensitivity/Response | Somatic | 2 | 25855885 | Detail |
| head and neck cancer | PTEN MUTATION PTEN MUTATION | D |
Predictive
|
Does Not Support
|
Sensitivity/Response | Somatic | 2 | 25855885 | Detail |
| head and neck cancer | PIK3CA MUTATION PIK3CA MUTATION | D |
Predictive
|
Does Not Support
|
Sensitivity/Response | Somatic | 2 | 25855885 | Detail |
| Her2-receptor positive breast cancer |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
D |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 3 | 22802530 | Detail |
| endometrial cancer | PIK3CA MUTATION PIK3CA MUTATION | D |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 3 | 23674493 | Detail |
| cervix carcinoma |
PIK3CA p.Glu545Lys (p.E545K) ( ENST00000263967.4, ENST00000643187.1 ) PIK3CA p.Glu545Lys (p.E545K) ( ENST00000263967.4, ENST00000643187.1 ) |
D |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 3 | 27489350 | Detail |
| breast cancer |
PIK3CA p.Glu545Lys (p.E545K) ( ENST00000263967.4, ENST00000643187.1 ) PIK3CA p.Glu545Lys (p.E545K) ( ENST00000263967.4, ENST00000643187.1 ) |
D |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 3 | 23888070 | Detail |
| lung adenocarcinoma | RIT1 MUTATION RIT1 MUTATION | D |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 3 | 24469055 | Detail |
| ovary epithelial cancer |
PIK3CA AMPLIFICATION ( ENST00000263967.4, ENST00000497599.5 ) PIK3CA AMPLIFICATION ( ENST00000263967.4 ) |
C |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 2 | 25370471 | Detail |
| melanoma |
BRAF p.Val640Glu (p.V640E) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) BRAF p.Val640Glu (p.V640E) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) |
C |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 2 | 25370471 | Detail |
| gastrointestinal stromal tumor | KIT MUTATION KIT MUTATION | D |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 2 | 23231951 | Detail |
Annotation
| Description | Associated Genes | Associated Variants | Sensitivity | Supported | Source | Links |
|---|---|---|---|---|---|---|
| Analysis of drug response data from the Sanger cen... | PIK3CA | PIK3CA MUTATION PIK3CA MUTATION | Sensitivity | false | CIViC Evidence | detail |
| Analysis of drug response data from the Sanger cen... | PTEN | PTEN MUTATION PTEN MUTATION | Sensitivity | false | CIViC Evidence | detail |
| 6 head and neck cancer cell lines were tested for ... | PIK3CA | PIK3CA MUTATION PIK3CA MUTATION | Sensitivity | false | CIViC Evidence | detail |
| The HER2/Neu mammary tumor mouse model MMTV-NeuT w... | ERBB2 |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
Sensitivity | true | CIViC Evidence | detail |
| A panel of 24 endometrioid endometrial cancer (EEC... | PIK3CA | PIK3CA MUTATION PIK3CA MUTATION | Sensitivity | true | CIViC Evidence | detail |
| CaSki cells that are heterozygous for the PIK3CA-E... | PIK3CA |
PIK3CA p.Glu545Lys (p.E545K) ( ENST00000263967.4, ENST00000643187.1 ) PIK3CA p.Glu545Lys (p.E545K) ( ENST00000263967.4, ENST00000643187.1 ) |
Sensitivity | true | CIViC Evidence | detail |
| PIK3CA E545K mutation increased sensitivity to AKT... | PIK3CA |
PIK3CA p.Glu545Lys (p.E545K) ( ENST00000263967.4, ENST00000643187.1 ) PIK3CA p.Glu545Lys (p.E545K) ( ENST00000263967.4, ENST00000643187.1 ) |
Sensitivity | true | CIViC Evidence | detail |
| RIT1 mutations were identified in approx. 2% of lu... | RIT1 | RIT1 MUTATION RIT1 MUTATION | Sensitivity | true | CIViC Evidence | detail |
| One platinum-refractory epithelial ovarian cancer ... | PIK3CA |
PIK3CA AMPLIFICATION ( ENST00000263967.4, ENST00000497599.5 ) PIK3CA AMPLIFICATION ( ENST00000263967.4 ) |
Sensitivity | true | CIViC Evidence | detail |
| One patient with BRAF V600E mutated melanoma (with... | BRAF |
BRAF p.Val640Glu (p.V640E) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) BRAF p.Val640Glu (p.V640E) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) |
Sensitivity | true | CIViC Evidence | detail |
| Human GISTs with different KIT mutations were graf... | KIT | KIT MUTATION KIT MUTATION | Sensitivity | true | CIViC Evidence | detail |
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT00960960 | Completed | Phase 1 | A Study of PI3-Kinase Inhibitor GDC-0941 in Combination With Paclitaxel, With and Without Bevacizumab or Trastuzumab, and With Letrozole, in Participants With Locally Recurrent or Metastatic Breast Cancer | August 2009 | December 2015 |
| NCT01493843 | Completed | Phase 2 | Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab With and Without Pictilisib in Previously Untreated Advanced or Recurrent Non-small Cell Lung Cancer | January 20, 2012 | March 30, 2016 |
| NCT00996892 | Terminated | Phase 1 | Safety, Tolerability and Pharmacokinetics of Cobimetinib in Combination With Pictilisib in Patients With Locally Advanced or Metastatic Solid Tumors | November 2009 | March 2014 |